文献速递颈动脉与弓上血管

伴中重度致残性缺血性卒中的颈动脉狭窄患者延迟血运重建的获益

The benefit of deferred carotid revascularization in patients with moderate-severe disabling cerebral ischemic stroke.
PubMed 文献 · J Vasc Surg · 2020-04-26

本研究回顾2007至2017年126例伴大体积脑缺血病灶(LVCIL,>4000 mm³)且改良Rankin量表(mRS)评分3或4的症状性颈动脉狭窄患者行颈动脉内膜切除术(CEA)的数据。围手术期卒中/死亡率为7.3%,4周内手术者显著高于4周后(11.9% vs 1.7%,P = .03)。4周后CEA者1年围手术期/复发性卒中显著低于未手术对照组(1.7% vs 13.9%,P = .02)。

要点

  • 伴LVCIL且mRS≥3的近期卒中患者CEA围手术期风险高,总体卒中/死亡7.3%。
  • 4周内行CEA与术后卒中/死亡独立相关(OR 8.2,95%CI 1.01-73)。
  • 延迟至4周后手术可显著降低围手术期/1年复发性卒中风险。

核心结论

  • 伴近期中重度缺血性卒中和大体积脑缺血病灶的患者行CEA手术风险高,但延迟超过4周后干预获益显著。

研究设计与样本

  • 回顾性队列研究,纳入2007至2017年4020例CEA中126例(2.9%)伴LVCIL和mRS 3或4的症状性颈动脉狭窄患者。
  • LVCIL定义为脑缺血病灶体积>4000 mm³,对照为同期101例因痴呆、严重合并症或预期寿命<1年而不适合CEA的患者。

主要发现

  • 患者中位年龄69岁(IQR 10岁),72%(91例)为男性,mRS中位3分(IQR 1),LVCIL体积中位20,000 mm³(IQR 47,000 mm³)。
  • 症状至CEA中位时间7周(IQR 8周),总体围手术期卒中/死亡7.3%(8例卒中,1例死亡)。
  • 4周内CEA者围手术期卒中/死亡11.9%(8/67),显著高于4周后1.7%(1/59)(P = .03)。
  • 多因素logistic回归显示4周内CEA是术后卒中/死亡的独立预测因素(OR 8.2,95%CI 1.01-73)。
  • 1年时,CEA后围手术期/复发性卒中与不适合CEA者相似(6.2% vs 13.9%,P = .11),但4周后CEA者显著更低(1.7% vs 13.9%,P = .02)。

临床怎么用

  • 对伴LVCIL和mRS≥3的近期卒中患者,可考虑将CEA延迟至4周以后以降低围手术期风险。

局限性

  • 回顾性设计,样本量较小(126例),对照组非随机且因合并症选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Symptomatic carotid artery stenosis needs revascularization within 2 weeks by carotid endarterectomy (CEA) to reduce the risk of symptom recurrence; however, the optimal timing of intervention is yet to be defined in patients with large-volume cerebral ischemic lesion (LVCIL) and modified Rankin scale (mRS) score ≥3. The aim of this study was to determine the most appropriate timing for CEA in patients with a recent stroke and LVCIL. METHODS: Data from patients with symptomatic carotid stenosis with LVCIL and mRS score of 3 or 4 from 2007 to 2017 were considered. Patients were submitted to CEA if they had a stable clinical condition and life expectancy >1 year. LVCIL was defined as a cerebral ischemic lesion of volume >4000 mm3. Perioperative stroke and death were evaluated by stratifying for timing of CEA by χ2 test and multiple logistic regression. Patients with similar characteristics (LVCIL and mRS score of 3 or 4) unfit for CEA served as the control group for recurrence of stroke at 1-year follow-up. RESULTS: In an 11-year period, of a total 4020 CEAs, 126 (2.9%) were performed in patients with a moderate stroke and LVCIL occurring in the same admission. The patients' median age was 69 years (interquartile range [IQR], 10 years); 72% (91) were male, with mRS score of 3 (IQR, 1) and LVCIL volume of 20,000 mm3 (IQR, 47,000 mm3). The median time elapsed from symptoms to CEA was 7 weeks (IQR, 8 weeks). Overall perioperative stroke/death was 7.3% (eight strokes and one death). By selective timing evaluation of the postoperative events, CEA performed within 4 weeks was associated with a significantly higher rate of stroke/death compared with patients operated on after 4 weeks: 11.9% (8/67) vs 1.7% (1/59; P = .03). By logistic regression, CEA within 4 weeks was an independent (from sex, cerebral ischemic lesion volume, dyslipidemia, and carotid stenosis) predictor of postoperative stroke/death (odds ratio, 8.2; 95% confidence interval, 1.01-73). In the same period, 101 patients were considered unfit for CEA for dementia (n = 22), severe comorbidities (n = 55), or short (<1-year) life expectancy (n = 24), and 43 (43%) survived at 1 year. At 1 year, the perioperative/recurrent stroke after CEA vs patients unfit for CEA was similar (6.2% vs 13.9%; P = .11), but CEA performed after 4 weeks led to significantly lower perioperative/recurrent stroke (1.7% vs 13.9%; P = .02). CONCLUSIONS: The surgical risk of CEA in patients with a recent moderate-severe ischemic stroke and LVCIL is high. However, if the intervention is delayed >4 weeks, its benefit seems significant.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Pini R, Faggioli G, Vacirca A, et al. The benefit of deferred carotid revascularization in patients with moderate-severe disabling cerebral ischemic stroke. J Vasc Surg. 2020. PMID: 32348801. doi:10.1016/j.jvs.2020.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。